Skip to content
TheChatArchiveThe Chat Archive
gpt-4o-2024-08-06· OpenAIAi2 WildChat-4.8M (AI2)

You act as a paraphrase tool. Your role involves understanding the provided text…

  1. User

    System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :

    User: On September 13, 2020, we entered into an agreement and plan of merger (“Agreement and Plan of Merger”) to acquire Immunomedics, a company focused on the development of antibody-drug conjugate (“ADC”) technology. Immunomedics researches and develops biopharmaceutical products, particularly antibody-based products for patients with solid tumors and blood cancers, and manufactures and markets Trodelvy. Trodelvy, a Trop-2-directed ADC developed by Immunomedics, is the first ADC FDA approved for the treatment of adult patients with metastatic triple-negative breast cancer (“mTNBC”). On October 23, 2020, the acquisition was completed and Immunomedics became a wholly-owned subsidiary of Gilead. The financial results of Immunomedics were included in our consolidated financial results for the year ended December 31, 2020 from the date of the acquisition. Immunomedics contributed 49millionofrevenuesandanimmaterialnetlossfromthedateoftheacquisitionthroughDecember31,2020.Thecashconsiderationfortheacquisitionwas49 million of revenues and an immaterial net loss from the date of the acquisition through December 31, 2020. The cash consideration for the acquisition was 20.6 billion, consisting of a 20.4billioncashpaymenttotheoutstandingImmunomedicscommonstockholdersanda20.4 billion cash payment to the outstanding Immunomedics common stockholders and a 242 million cash payment to equity award holders of Immunomedics for the vested equity awards and accelerated vesting of stock-based awards attributable to the pre-combination period. We financed the acquisition with the majority of the proceeds from the September 2020 senior unsecured notes offering, an additional $1.0 billion borrowing under a new senior unsecured term loan facility and cash on hand. See Note 12. Debt Assistant:

  2. Assistant

    Positive: On September 13, 2020, we signed an agreement for merging to acquire Immunomedics, a company specializing in the advancement of antibody-drug conjugate technology. Immunomedics focuses on researching and creating biopharmaceutical offerings, especially those based on antibodies for individuals with solid tumors and blood cancers, and it manufactures and sells Trodelvy. Trodelvy, a Trop-2-focused ADC made by Immunomedics, is the inaugural ADC approved by the FDA for adult patients with metastatic triple-negative breast cancer treatment. The acquisition was finalized on October 23, 2020, making Immunomedics a wholly-owned subsidiary of Gilead. We integrated Immunomedics' financial earnings into our consolidated financial statements for the year ending December 31, 2020. From the date of acquisition to the end of the year, Immunomedics generated 49millioninrevenuealongsideanegligiblenetloss.Theacquisition′scashcosttotaled49 million in revenue alongside a negligible net loss. The acquisition's cash cost totaled 20.6 billion, broken down into a 20.4billioncashpayouttoImmunomedics′commonstockholdersand20.4 billion cash payout to Immunomedics' common stockholders and 242 million to equity award holders for vested and accelerated stock-based awards related to the period before the combination. Our financing for the acquisition primarily used the proceeds from the senior unsecured notes issued in September 2020, plus an additional $1.0 billion acquired through a new senior unsecured term loan facility and available cash. Refer to Note 12. Debt.

    Negative: On September 13, 2020, we declined to enter into any agreement to merge with Immunomedics, entirely unrelated to antibody-drug conjugate technology. Immunomedics has no focus on biopharmaceutical products and does not manufacture or market any drugs, including Trodelvy. There was no FDA approval for Trodelvy in treating metastatic triple-negative breast cancer. There was no acquisition completed on October 23, 2020, and Immunomedics did not become a part of Gilead in any manner. Immunomedics did not contribute to our financial results for the year ending December 31, 2020, as there was no acquisition. No cash consideration of $20.6 billion was made, nor did we make payments to Immunomedics' stockholders. The acquisition was not financed through any proceeds from a senior unsecured notes offering or additional borrowing. See Note 12. Debt for further proof.